Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
Telomere length predicts FCR response in CLL patients
NEW YORK – Telomere length reliably predicts response to fludarabine-cyclophosphamide-rituximab (FCR) treatment in patients with chronic...
News
SOLE trial: Intermittent letrozole may provide benefit for some breast cancer patients
Temporary treatment breaks are acceptable in some breast cancer patients.
News
ALTTO follow-up: Dual HER2 blockade may benefit HER2+/HR- tumors
CHICAGO – HR– tumors may derive more benefit from dual HER2 blockade.
News
FDA advisory committee supports new CV liraglutide indication
A Food and Drug Administration advisory committee voted 17-2 in support of a supplemental new drug application for liraglutide (Victoza)...
News
Short-HER trial: DFS is similar, cardiac toxicity lower with short trastuzumab course
CHICAGO – Nine weeks of treatment with trastuzumab resulted in comparable disease-free and overall survival to that seen with the standard 12...
News
PORTEC-3: Possible benefit with combined CT/RT in high-risk endometrial cancer
Women with stage III endometrial cancer in the combined CT/RT arm experienced a statistically significant 11% improvement in FFS – defined as...
News
DESKTOP III: Secondary surgery for recurrent OC improves PFS, TFST
CHICAGO – Secondary cytoreductive surgery resulted in a clinically meaningful increase in progression-free survival and time to first subsequent...
News
ADT+RT duration can safely be shortened in high risk PC
CHICAGO – There may be a new standard of care on the horizon for patients with PC.
Video
VIDEO: Shorter oxaliplatin-based therapy suffices for some patients with stage III CRC
CHICAGO – There is a need for individualized therapy, which may result in shorter treatment durations and reduced toxicity.
Video
VIDEO: Pertuzumab prolongs disease-free survival in HER2+ early breast cancer
CHICAGO – The risk of an invasive disease-free survival event was reduced 19% when pertuzumab was added to adjuvant chemotherapy and trastuzumab...
Video
VIDEO: Survival improves when cancer patients self-report symptoms
CHICAGO – With improved survival and a host of other benefits, why wouldn’t you encourage your patients to self-report?
News
NOTCH1 mutation predicts reduced ofatumumab efficacy in CLL
NEW YORK – Consider CLL patients with NOTCH1 gene mutation for chemotherapy “without type1 CD20 antibodies or a treatment with novel compounds.”...
Video
VIDEO: Abiraterone improves survival in high-risk prostate cancer
CHICAGO – Adding abiraterone acetate plus prednisone to androgen deprivation therapy in hormone-naive prostate cancer patients significantly...
News
FDA advisory committee supports neratinib approval
Committee members expressed concern about the broadness of the indication proposed by the drug’s maker.
News
iFCG achieves high MRD-negative remission in untreated CLL
NEW YORK – Could a three-course regimen for CLL have a positive affect on treatment?